Correlation Between Straumann Holding and Basilea Pharmaceutica

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Straumann Holding and Basilea Pharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Straumann Holding and Basilea Pharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Straumann Holding AG and Basilea Pharmaceutica AG, you can compare the effects of market volatilities on Straumann Holding and Basilea Pharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Straumann Holding with a short position of Basilea Pharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Straumann Holding and Basilea Pharmaceutica.

Diversification Opportunities for Straumann Holding and Basilea Pharmaceutica

0.87
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Straumann and Basilea is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Straumann Holding AG and Basilea Pharmaceutica AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Basilea Pharmaceutica and Straumann Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Straumann Holding AG are associated (or correlated) with Basilea Pharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Basilea Pharmaceutica has no effect on the direction of Straumann Holding i.e., Straumann Holding and Basilea Pharmaceutica go up and down completely randomly.

Pair Corralation between Straumann Holding and Basilea Pharmaceutica

Assuming the 90 days trading horizon Straumann Holding AG is expected to under-perform the Basilea Pharmaceutica. But the stock apears to be less risky and, when comparing its historical volatility, Straumann Holding AG is 1.2 times less risky than Basilea Pharmaceutica. The stock trades about -0.01 of its potential returns per unit of risk. The Basilea Pharmaceutica AG is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  4,120  in Basilea Pharmaceutica AG on October 11, 2024 and sell it today you would earn a total of  195.00  from holding Basilea Pharmaceutica AG or generate 4.73% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Straumann Holding AG  vs.  Basilea Pharmaceutica AG

 Performance 
       Timeline  
Straumann Holding 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Straumann Holding AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.
Basilea Pharmaceutica 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Basilea Pharmaceutica AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Basilea Pharmaceutica is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Straumann Holding and Basilea Pharmaceutica Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Straumann Holding and Basilea Pharmaceutica

The main advantage of trading using opposite Straumann Holding and Basilea Pharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Straumann Holding position performs unexpectedly, Basilea Pharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will offset losses from the drop in Basilea Pharmaceutica's long position.
The idea behind Straumann Holding AG and Basilea Pharmaceutica AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEOs Directory
Screen CEOs from public companies around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets